Company Overview of Materia Medica Holdings Ltd.
Materia Medica Holdings Ltd. engages in the research and manufacturing of homeopathic products. It offers Anaferon, a drug for prevention and treatment of influenza and SARS; Anaferon for children for the treatment and prevention of influenza; Arthrofoon, a drug for course treatment of chronic inflammatory diseases of joints; Afala, a drug for treatment of prostatitis and benign prostate hyperplasia; and Impaza, a product for course treatment of erectile dysfunction of different etiology. The company also provides Proproten-100, a drug for the treatment of alcoholism; Tenoten for acute and chronic stresses and neurosis-like conditions; and Tenoten for children for the treatment of attention ...
3rd Samotechniy per
Founded in 1992
Key Executives for Materia Medica Holdings Ltd.
Materia Medica Holdings Ltd. does not have any Key Executives recorded.
Materia Medica Holdings Ltd. Key Developments
Angel Biotechnology Holdings Plc Confirms Key Parameters of the Joint Venture Agreement with Materia Medica Holdings Ltd
Dec 3 12
Angel Biotechnology Holdings Plc announced following detailed negotiations in Moscow held on 29 and 30 November 2012, the company confirmed that the key parameters of the joint venture agreement with Materia Medica Holdings Ltd. (OOO NPF Materia Medica Holding ("MMH")) have now been agreed and that completion of legalities and signing of the agreement remain on course for completion before the end of the calendar year. The agreement provides for the transfer of all existing contracts currently carried out by Angel for MMH to the JV company in which Angel will have a minority stake. The terms upon which such contracts are to be transferred will likely give rise to an exceptional book loss in the interim accounts of circa £1.7 million, a substantial portion of which is expected to be recovered in future periods, and a further write off of accrued income in respect of the contracts of circa £0.35 million. Because the liability created will be paid for through the transfer of fixed assets, licensing support and the achievement of milestones by the JV company, the transfer of contracts to the JV is expected to be cash neutral for the Group.
Materia Medica Holdings Ltd. Announces Executive Changes
Nov 5 12
Materia Medica Holdings Ltd. named John Naylor senior vice president of commercial markets, effective November 19, 2012. Naylor replaces Simeon Schindelman, who has taken the position of CEO of Bloom Health. Naylor joined Medica as vice president and general manager of commercial sales in April 2010.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries